GlobeNewswire by notified

BioAegis Therapeutics Unveils Upcoming Clinical Study of Gelsolin, an Immune Regulator, as a Treatment for Patients with Acute Respiratory Distress Syndrome (ARDS)

Share

Large phase 2 global study will evaluate efficacy and safety of recombinant human plasma gelsolin (rhu-pGSN) for moderate-to-severe ARDS.

NORTH BRUNSWICK, N.J., Feb. 27, 2024 (GLOBE NEWSWIRE) -- BioAegis Therapeutics, a pioneering biotech company at the forefront of innovative therapies for inflammatory diseases, is pleased to announce site recruitment for BTI-203, a Phase 2 study of recombinant human gelsolin (rhu-pGSN) for the treatment of Acute Respiratory Distress Syndrome (ARDS) (NCT05947955).

The study, A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Adjunctive Recombinant Human Plasma Gelsolin With Standard of Care for Moderate-to-Severe ARDS Due to Pneumonia or Other Infections is being conducted under a contract with BARDA’s Division of Research, Innovation, and Ventures (DRIVe), part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services.

Approximately 80 sites in the US, Canada, UK and the EU, including Belgium, France, Italy, Germany, Netherlands, Spain and others will conduct the study. Enrollment is targeted for 600 subjects. The planned primary outcomes are all-cause mortality at Day 28 between treatment groups and incidence, causality, and severity of SAEs in rhu-pGSN vs placebo treatment.

Effectively Treating ARDS will Reduce Society’s Vulnerability to Global Pandemics
ARDS is a condition that can develop as a severe complication of sepsis, trauma, pneumonia or other infectious diseases, resulting in life-threatening lung injury with fluid leakage into the lungs. Breathing becomes difficult and patients require oxygen, mechanical ventilation and extensive critical care resources, placing a significant burden on the healthcare system.

Even with aggressive medical management, a substantial number of patients do not survive, and those who do may suffer from long-term complications, including impaired lung function and reduced quality of life. In the U.S. alone, ARDS affects over 700,000 patients per year or roughly 10% of all ICU admissions. The mortality rate for ARDS is approximately 40%. The lack of effective therapies to treat ARDS and its associated high mortality driven by excess inflammation underscores the urgent need for an innovative therapy in this field.

Plasma Gelsolin: A Multitasking Protein for a Complex Condition
Plasma gelsolin holds immense promise as a therapeutic intervention for ARDS due to its multifaceted mechanism of action. Gelsolin has demonstrated the ability to:

  • Modulate the activation of the NLRP3 inflammasome and generation of IL-1β-containing microparticles
  • Facilitate uptake and killing of microbial pathogens by innate immune cells
  • Bind to and remove harmful inflammatory mediators
  • Regulate macrophage phenotype to modulate inflammation

Gelsolin is a naturally occurring human protein found in the bloodstream, which is depleted by counteracting the inflammatory process. Supplementation with the recombinant gelsolin protein holds promise to address the overzealous inflammatory response associated with ARDS.

"ARDS is significant source of mortality as well as a drain on healthcare resources across the globe. We are committed to reaching our goal of saving lives by addressing the challenges of this complex disease," stated Susan Levinson, Ph.D., Chief Executive Officer of BioAegis.

This project has been supported in whole or in part with federal funds from the U.S. Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority, under contract number 75A50123C00067.

About BioAegis
BioAegis Therapeutics Inc. is a NJ-based clinical-stage, private company whose mission is to capitalize on a key component of the body’s innate immune system, plasma gelsolin, to prevent adverse outcomes in diseases driven by inflammation and infection.

BioAegis’ platform is built upon the recombinant form of plasma gelsolin, a highly conserved abundant human protein in healthy individuals. Its role is to keep inflammation localized to the site of injury and to boost the body’s ability to clear pathogens. Normal levels of pGSN are depleted by diverse inflammatory conditions. Restoring gelsolin levels with the human recombinant form, rhu-pGSN, helps immune cells fight infection and controls inflammation so it does not spread and cause organ damage. Rhu-pGSN is a non-antibiotic, host-directed, non-immunosuppressive treatment for inflammation due to both infectious and non-infectious causes.

BioAegis has the exclusive license to broad, worldwide intellectual property through Harvard-Brigham and Women’s Hospital. It holds over 40 patents issued for coverage of inflammatory disease, infection, renal failure, and neurologic disease. BioAegis will also have US biologics exclusivity and has recently filed new IP in areas of unmet need.

Investor Inquiries:
Steven Cordovano
203-952-6373
scordovano@bioaegistx.com

Media Inquiries:
Christine Lagana
clagana@bioaegistx.com

This press release contains express or implied forward-looking statements, which are based on current expectations of management.  These statements relate to, among other things, our expectations regarding management’s plans, objectives, and strategies.  These statements are neither promises nor guarantees but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements.  BioAegis assumes no obligation to update any forward-looking statements appearing in this press release in the event of changing circumstances or otherwise, and such statements are current only as of the date they are made.


To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Cortus Energy AB deltar på Nordbex projektlansering för satsning på koldioxidnegativ elproduktion i Nybro kommun den 18 april17.4.2024 08:00:00 CEST | Pressemelding

Stockholm, den 17 april 2024 PRESSMEDDELANDE Cortus Energy AB (”Cortus Energy” eller ”Bolaget”) deltar på projektlansering om koldioxidnegativ elproduktion, tillsammans med samarbetsparter Nordbex AB (”Nordbex”). Nordbex presenterar sin satsning och ambitionen att göra Nybro kommun koldioxidnegativ innan 2030 genom ett koldioxidnegativt kraftverk med Cortus Energys förgasningsteknologi, WoodRoll®. Under projektlanseringen kommer den svenska projektutvecklaren Nordbex presentera miljardsatsningen på koldioxidnegativ elproduktion som görs i Nybro kommun. Det första koldioxidnegativa kraftverket ska byggas av Nordbex, där Cortus WoodRoll®-förgasningsteknologi har en central roll till följd av den rena syngasen som produceras. Nordbex kraftverk kommer att generera 135 GWh ren energi och samla in 200 000 ton koldioxid från atmosfären varje år. Projektlanseringen inleds med en presentation av Nordbex, vilken går att följa live från och med kl 16:00 den 18 april på följande länk https://www.y

Norsk Hydro: Reminder - Invitation to Hydro's first quarter results 202417.4.2024 08:00:00 CEST | Press release

Hydro's first quarter results 2024 will be released at 07:00 CEST (01:00 EDT, 06:00 BST, 05:00 UTC/GMT) on Wednesday, April 24, 2024. The quarterly report and presentation will be available on hydro.com at the same time. President and CEO Hilde Merete Aasheim and Executive Vice President, Corporate Development & acting CFO Trond Olaf Christophersen will host a webcast in English at 08:30 CEST the same day. There will be a Q&A session directly after the presentation. There will be no presentation or press conference at our corporate headquarters. To join the webcast and ask questions, register your details in the webcast page. Once registered, you will receive a separate email confirming your registration. The webcast is powered by Livestorm. We advise that you investigate in advance if your company has any restrictions using this platform. Investor contact: Martine Rambøl Hagen +47 91708918 martine.rambol.hagen@hydro.com

Roche’s subcutaneous OCREVUS one-year data demonstrates near-complete suppression of clinical relapses and brain lesions in patients with progressive and relapsing forms of MS17.4.2024 08:00:00 CEST | Press release

Results from the Phase III study showed that subcutaneous (SC) injection was consistent with IV infusion and demonstrated near-complete suppression of relapse activity (97%) and MRI lesions (97.2%) through 48 weeksThe twice-yearly, 10-minute SC injection has the potential to expand the usage of OCREVUS to treatment centres without IV infrastructure or with IV capacity limitationsU.S. FDA and EMA accepted filings based on the data from OCARINA II, with EU approval anticipated mid-2024 and U.S. approval anticipated September 2024 Basel, 17 April 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today data from the Phase III OCARINA II study (S31.006) of OCREVUS® (ocrelizumab), an investigational twice-yearly, 10-minute subcutaneous (SC) injection. Results showed near-complete suppression of clinical relapses and brain lesions in people with relapsing or primary progressive multiple sclerosis (RMS or PPMS) which reinforce the potential benefits of this investigational formulation. Treat

Nilörn Interim Report Q1, 202417.4.2024 08:00:00 CEST | Press release

Period January - March Order intake increased by 5 percent to MSEK 233 (223)Revenue increased by 10 percent to MSEK 242 (221)Revenue adjusted for currency effects amounted to MSEK 243 (221), i.e., an underlying organic increase of 10 percentOperating profit amounted to MSEK 22.5 (16.9)Net profit for the period amounted to MSEK 16.7 (11.1)Earnings per share amounted to SEK 1.46 (0.97)Net cash excluding IFRS 16 amounted to MSEK 8 (43) Significant during the quarter The board has decided to propose to the annual general meeting a dividend of SEK 1.00 (5.00) per share, equivalent to MSEK 11.4 (57.0)Nilorngruppen has initiated a strategic collaboration with Worldfavor, strengthening the Nilorn:CONNECT solution and offer to our customers on their journey towards the Digital Product Passport. A presentation will be held today 17/4 at 08.30 am CET, where the CEO presents the report. You can participate by register on the link below: Registration Form For further information about Nilörn, pleas

Nilörn Delårsrapport Q1, 202417.4.2024 08:00:00 CEST | Pressemelding

Perioden januari - mars Orderingången ökade med 5 procent till 233 (223) MSEKOmsättningen i SEK ökade med 10 procent till 242 (221) MSEKOmsättningen justerat för valutaeffekter uppgick till 243 (221) MSEK, dvs en underliggande organisk ökning om 10 procentRörelseresultatet uppgick till 22,5 (16,9) MSEKPeriodens resultat uppgick till 16,7 (11,1) MSEKResultatet per aktie uppgick till 1,46 (0,97) SEKNettokassan (exklusive IFRS16) uppgick till 8 (43) MSEK Väsentliga händelser under kvartalet Styrelsen har beslutat att föreslå årsstämman en utdelning om 1,00 (5,00) kronor per aktie, motsvarande 11,4 (57,0) MSEKNilörn har inlett ett strategiskt samarbete med Worldfavor, vilket stärker lösningen Nilörn:CONNECT och erbjudandet till våra kunder på deras resa mot det Digitala Produktpasset En presentation kommer hållas idag 17/4 kl. 08.30, där VD presenterar rapporten. Du kan delta genom att registrera dig på nedanstående länk: Registration Form För ytterligare information om Nilörn, kontakta: K

HiddenA line styled icon from Orion Icon Library.Eye